MSH2 and colorectal carcinoma: Path_MLH1 and path_MSH2 carriers showed a higher cumulative CRC risk than path_PMS2 carriers (Figure 4B, log-rank test MLH1 vs. PMS2 p = 0.03; MSH2 vs. PMS2 p = 0.03).